4 chapters across the catalog
Genetic testing company 23andMe has filed for bankruptcy protection following years of financial challenges, leading CEO Anne Wojcicki to resign. The California Attorney General has urged customers to request the deletion of their data and the destruction of genetic samples to prevent them from being sold during the liquidation process. This development follows decade-long warnings from privacy advocates regarding the long-term security of personal DNA databases.
23andMe Board Resignations and Potential Privatization
The entire board of directors at 23andMe has resigned following a disagreement with CEO Anne Wojcicki over her proposal to take the company private. The genetic testing firm faces a potential Nasdaq delisting as its stock price has fallen below one dollar. Concerns are raised regarding the security of consumer DNA data as the company struggles with financial instability and a lack of independent oversight.
The FDA issued a warning letter to genetic testing company 23andMe, effectively halting its health-related diagnostic services. The hosts discuss the regulatory conflict, noting that the FDA views the saliva collection kit as an unapproved medical device. They argue that the company's marketing of disease risk, such as BRCA mutations, is misleading without professional genetic counseling.
The hosts criticize the "disruptive" mentality of Silicon Valley, specifically targeting 23andMe CEO Anne Wojcicki and investors like Google's Sergey Brin. They claim the company's true business model is not providing health insights to users, but rather building a massive genetic database to sell to pharmaceutical firms.
